Ponesimod is an orally active selective sphingosine-1-phosphate receptor 1 modulator under investigation for the treatment of multiple sclerosis. This was a single-centre, double-blind, randomized, placebo- and positive-controlled parallel-group study investigating the effects of ponesimod on the QTc interval in healthy individuals. A nested cross-over comparison between moxifloxacin and placebo was included in the combined moxifloxacin/placebo treatment group. Subjects in group A received multiple doses of 10-100 mg ponesimod according to an uptitration regimen on days 2-23 and moxifloxacin-matching placebo on days 1 and 24. Subjects in group B received ponesimod-matching placebo on days 2-23 and were randomized to receive either a single dose of 400 mg moxifloxacin or matching placebo on days 1 and 24. The primary end-point was the baseline-adjusted, placebo-corrected effect on the individually corrected QT interval (QTcI) on days 12 (after 5 days of 40 mg ponesimod) and 23 (after 5 days of 100 mg ponesimod). Ponesimod caused a mild QTcI prolongation with a largest effect of 6.9 ms (90% two-sided confidence interval (CI): 2.5-11.3) and 9.1 ms (90% CI: 4.1-14.0) for doses of 40 mg and 100 mg, respectively. A concentration-effect analysis confirmed the QTcI-prolonging effect of ponesimod with a shallow slope of 0.0053 ms per ng/mL. Using the concentration-effect analysis, the QTc prolongation caused by 20 mg ponesimod and the current highest therapeutic dose was predicted to be below the level of clinical concern (i.e. an upper bound of the two-sided 90% CI of ≥10 ms).

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcpt.12336DOI Listing

Publication Analysis

Top Keywords

placebo days
12
ponesimod
9
receptor modulator
8
interval healthy
8
healthy individuals
8
subjects group
8
group received
8
days 2-23
8
concentration-effect analysis
8
days
7

Similar Publications

Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end-stage kidney disease on dialysis. Characteristics of currently available phosphate binders that lead to poor patient experiences such as large drug volume size of required daily medication (e.g.

View Article and Find Full Text PDF

Habitual pre-exercise caffeine supplementation prevents exercise-training induced attenuation of exercising systolic blood pressure and double-product.

J Appl Physiol (1985)

December 2024

Integrative Laboratory of Applied Physiology & Lifestyle Medicine, Department of Health and Human Physiology, University of Iowa, Iowa City, IA, USA.

We examined the effect of habitual pre-exercise caffeine supplementation on training-induced adaptations to exercising systolic (SBP), diastolic (DBP), pulse pressure (PP), heart rate (HR), and double product (DP). Young women (mean±SD; 24±7 y) were randomized to a caffeine (120 mg) supplement (CAF; n=17) or placebo (PLA; n=16) group, completed 6-weeks of high intensity exercise training on three non-consecutive days per week, and supplemented with CAF or PLA 30-60 minutes before exercise or else upon waking. Before (PRE) and after (POST) the intervention, SBP, DBP, and HR were measured, and PP and DP calculated, at rest and during fixed-power exercise at 50W and 75W.

View Article and Find Full Text PDF

The prevalence of individuals with overweight and obesity has increased by 18% since 1990 and it is projected that by 2030, nearly 50% of US adults will have obesity. Lifestyle modifications, such as diet and exercise, typically lead to approximately 3-5% weight loss, whereas 5-15% weight loss is necessary to significantly impact obesity-associated comorbidities and improve overall health outcomes. In addition to lifestyle modifications, pharmacotherapy has been utilized as an adjunctive treatment to increase weight loss and improve health outcomes.

View Article and Find Full Text PDF

Background: Traumatic Brain Injury (TBI) is a leading cause of hospitalization and disability in young and middle-aged adults. This study aims to survey the efficacy of oral modafinil, a low-side-effect central nervous system stimulant, in the enhancement of consciousness recovery in moderate to severe TBI patients in the ICUs of a referral trauma center.

Materials And Methods: All ICU patients meeting inclusion criteria between April 2021 and April 2023 were screened.

View Article and Find Full Text PDF

An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans.

Psychopharmacology (Berl)

December 2024

Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, Maastricht, 6200 MD, The Netherlands.

Rationale: Despite the growing scientific interest on mitragynine, the primary alkaloid in kratom (Mitragyna Speciosa), there is a lack of clinical trials in humans.

Objectives: This phase 1 study aimed to evaluate mitragynine's safety profile and acute effects on subjective drug experience, neurocognition, and pain tolerance.

Methods: A placebo-controlled, single-blind, within-subjects study was conducted in two parts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!